Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, March 20, 2015, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.57 to $48,050,000.00.

Highlighted Stocks Traded by Insiders:

Shutterfly (SFLY) - FREE Research Report

McCormick Dan, who is SVP, Chief Operating Officer at Shutterfly, sold 44,443 shares at $48.22 on March 20, 2015. Following this transaction, the SVP, Chief Operating Officer owned 78,375 shares meaning that the stake was reduced by 36.19% with the 44,443-share transaction.

The shares most recently traded at $48.75, up $0.53, or 1.08% since the insider transaction. Historical insider transactions for Shutterfly go as follows:

  • 4-Week # shares bought: 15,000
  • 4-Week # shares sold: 135,439
  • 12-Week # shares bought: 15,000
  • 12-Week # shares sold: 148,439
  • 24-Week # shares bought: 15,000
  • 24-Week # shares sold: 158,769

The average volume for Shutterfly has been 557,400 shares per day over the past 30 days. Shutterfly has a market cap of $1.8 billion and is part of the services sector and diversified services industry. Shares are up 16.3% year-to-date as of the close of trading on Friday.

Shutterfly, Inc. manufactures and retails in digital personalized products and services in the United States. It offers a range of personalized photo-based products and services for consumers to upload, edit, enhance, organize, find, share, create, print, and preserve their memories. Currently, there are 9 analysts who rate Shutterfly a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SFLY - FREE

TheStreet Quant Ratings rates Shutterfly as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. Get the full Shutterfly Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Nuance Communications (NUAN) - FREE Research Report

Robbins William T, who is Executive Vice President World at Nuance Communications, sold 2,500 shares at $14.25 on March 20, 2015. Following this transaction, the Executive Vice President World owned 193,728 shares meaning that the stake was reduced by 1.27% with the 2,500-share transaction.

The shares most recently traded at $14.22, down $0.03, or 0.21% since the insider transaction. Historical insider transactions for Nuance Communications go as follows:

  • 4-Week # shares bought: 11,657
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 11,657
  • 12-Week # shares sold: 301,423
  • 24-Week # shares bought: 11,657
  • 24-Week # shares sold: 318,423

The average volume for Nuance Communications has been 2.2 million shares per day over the past 30 days. Nuance Communications has a market cap of $4.6 billion and is part of the technology sector and computer software & services industry. Shares are down 0.63% year-to-date as of the close of trading on Friday.

Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. Currently, there are 2 analysts who rate Nuance Communications a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUAN - FREE

TheStreet Quant Ratings rates Nuance Communications as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Nuance Communications Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Bell Leonard, who is Ceo at Alexion Pharmaceuticals, sold 15,952 shares at $188.07 on March 20, 2015. Following this transaction, the Ceo owned 949,426 shares meaning that the stake was reduced by 1.65% with the 15,952-share transaction.

The shares most recently traded at $184.46, down $3.61, or 1.96% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 1,465
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 29,041
  • 24-Week # shares bought: 510
  • 24-Week # shares sold: 63,644

The average volume for Alexion Pharmaceuticals has been 1.2 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $38.2 billion and is part of the health care sector and drugs industry. Shares are up 1.45% year-to-date as of the close of trading on Friday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 58.0. Currently, there are 14 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null